Mahmudul Alam
Bangladesh Agricultural University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mahmudul Alam.
Clinical Cancer Research | 2016
Magdalena Klanova; Ladislav Andera; Simona Benesova; Jan Soukup; Dana Prukova; Dana Vejmelkova; Radek Jaksa; Karel Helman; Petra Vockova; Lucie Lateckova; Jan Molinsky; Bokang Maswabi; Mahmudul Alam; Roman Kodet; Robert Pytlik; Marek Trneny; Pavel Klener
Purpose: To investigate the roles of BCL2, MCL1, and BCL-XL in the survival of diffuse large B-cell lymphoma (DLBCL). Experimental designs: Immunohistochemical analysis of 105 primary DLBCL samples, and Western blot analysis of 18 DLBCL cell lines for the expression of BCL2, MCL1, and BCL-XL. Pharmacologic targeting of BCL2, MCL1, and BCL-XL with ABT-199, homoharringtonine (HHT), and ABT-737. Analysis of DLBCL clones with manipulated expressions of BCL2, MCL1, and BCL-XL. Immunoprecipitation of MCL1 complexes in selected DLBCL cell lines. Experimental therapy aimed at inhibition of BCL2 and MCL1 using ABT-199 and HHT, single agent, or in combination, in vitro and in vivo on primary cell-based murine xenograft models of DLBCL. Results: By the pharmacologic targeting of BCL2, MCL1, and BCL-XL, we demonstrated that DLBCL can be divided into BCL2-dependent and MCL1-dependent subgroups with a less pronounced role left for BCL-XL. Derived DLBCL clones with manipulated expressions of BCL2, MCL1, and BCL-XL, as well as the immunoprecipitation experiments, which analyzed MCL1 protein complexes, confirmed these findings at the molecular level. We demonstrated that concurrent inhibition of BCL2 and MCL1 with ABT-199 and HHT induced significant synthetic lethality in most BCL2-expressing DLBCL cell lines. The marked cytotoxic synergy between ABT-199 and HHT was also confirmed in vivo using primary cell-based murine xenograft models of DLBCL. Conclusions: As homoharringtonine is a clinically approved antileukemia drug, and ABT-199 is in advanced phases of diverse clinical trials, our data might have direct implications for novel concepts of early clinical trials in patients with aggressive DLBCL. Clin Cancer Res; 22(5); 1138–49. ©2015 AACR.
Molecules | 2015
Ondřej Lidický; Olga Janoušková; J. Strohalm; Mahmudul Alam; Pavel Klener; Tomáš Etrych
Here we describe the synthesis and biological properties of two types of star-shaped polymer-doxorubicin conjugates: non-targeted conjugate prepared as long-circulating high-molecular-weight (HMW) polymer prodrugs with a dendrimer core and a targeted conjugate with the anti-CD20 monoclonal antibody (mAb) rituximab (RTX). The copolymers were linked to the dendrimer core or to the reduced mAb via one-point attachment forming a star-shaped structure with a central antibody or dendrimer surrounded by hydrophilic polymer chains. The anticancer drug doxorubicin (DOX) was attached to the N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymer chain in star polymer systems via a pH-labile hydrazone linkage. Such polymer-DOX conjugates were fairly stable in aqueous solutions at pH 7.4, and the drug was readily released in mildly acidic environments at pH 5–5.5 by hydrolysis of the hydrazone bonds. The cytotoxicity of the polymer conjugates was tested on several CD20-positive or negative human cell lines. Similar levels of in vitro cytotoxicity were observed for all tested polymer conjugates regardless of type or structure. In vivo experiments using primary cell-based murine xenograft models of human diffuse large B-cell lymphoma confirmed the superior anti-lymphoma efficacy of the polymer-bound DOX conjugate when compared with the original drug. Targeting with RTX did not further enhance the anti-lymphoma efficacy relative to the non-targeted star polymer conjugate. Two mechanisms could play roles in these findings: changes in the binding ability to the CD-20 receptor and a significant loss of the immunological properties of RTX in the polymer conjugates.
PLOS ONE | 2015
Lucie Lorkova; Michaela Scigelova; Tabiwang N. Arrey; Ondrej Vit; Jana Pospisilova; Eliska Doktorova; Magdalena Klanova; Mahmudul Alam; Petra Vockova; Bokang Maswabi; Pavel Klener; Jiri Petrak
Mantle cell lymphoma (MCL) is a chronically relapsing aggressive type of B-cell non-Hodgkin lymphoma considered incurable by currently used treatment approaches. Fludarabine is a purine analog clinically still widely used in the therapy of relapsed MCL. Molecular mechanisms of fludarabine resistance have not, however, been studied in the setting of MCL so far. We therefore derived fludarabine-resistant MCL cells (Mino/FR) and performed their detailed functional and proteomic characterization compared to the original fludarabine sensitive cells (Mino). We demonstrated that Mino/FR were highly cross-resistant to other antinucleosides (cytarabine, cladribine, gemcitabine) and to an inhibitor of Bruton tyrosine kinase (BTK) ibrutinib. Sensitivity to other types of anti-lymphoma agents was altered only mildly (methotrexate, doxorubicin, bortezomib) or remained unaffacted (cisplatin, bendamustine). The detailed proteomic analysis of Mino/FR compared to Mino cells unveiled over 300 differentially expressed proteins. Mino/FR were characterized by the marked downregulation of deoxycytidine kinase (dCK) and BTK (thus explaining the observed crossresistance to antinucleosides and ibrutinib), but also by the upregulation of several enzymes of de novo nucleotide synthesis, as well as the up-regulation of the numerous proteins of DNA repair and replication. The significant upregulation of the key antiapoptotic protein Bcl-2 in Mino/FR cells was associated with the markedly increased sensitivity of the fludarabine-resistant MCL cells to Bcl-2-specific inhibitor ABT199 compared to fludarabine-sensitive cells. Our data thus demonstrate that a detailed molecular analysis of drug-resistant tumor cells can indeed open a way to personalized therapy of resistant malignancies.
International Journal of Cancer | 2016
Pavel Klener; Eva Fronkova; Adela Berkova; Radek Jaksa; Halka Lhotska; Kristina Forsterova; Jan Soukup; Vojtech Kulvait; Jarmila Vargova; Karel Fiser; Dana Prukova; Mahmudul Alam; Bokang Maswabi; Kyra Michalova; Zuzana Zemanova; Tereza Jancuskova; Sona Pekova; Marek Trneny
Richter syndrome represents the transformation of the chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most frequently the diffuse large B‐cell lymphoma (DLBCL). In this report we describe a patient with CLL, who developed a clonally‐related pleomorphic highly‐aggressive mantle cell lymphoma (MCL) after five cycles of a fludarabine‐based second‐line therapy for the first relapse of CLL. Molecular cytogenetic methods together with whole‐exome sequencing revealed numerous gene alterations restricted to the MCL clone (apart from the canonical t(11;14)(q13;q32) translocation) including gain of one copy of ATM gene or emergence of TP53, CREBBP, NUP214, FUBP1 and SF3B1 gene mutations. Similarly, gene expression analysis revealed vast differences between the MCL and CLL transcriptome, including overexpression of cyclin D1, downregulation of cyclins D2 and D3, or downregulation of IL4R in the MCL clone. Backtracking analysis using quantitative PCR specifically detecting an MCL‐restricted focal deletion of TP53 revealed that the pre‐MCL clone appeared in the bone marrow and peripheral blood of the patient approximately 4 years before the clinical manifestation of MCL. Both molecular cytogenetic and sequencing data support the hypothesis of a slow development of the pre‐MCL clone in parallel to CLL over several years, and thereby exclude the possibility that the transformation event occurred at the stage of the CLL relapse clone by mere t(11;14)(q13;q32) acquisition.
Pakistan Journal of Biological Sciences | 2005
Mahmudul Alam; S.A. Islam .; Y. Mohammed .; Nasrin Sultana Juyena; M.A. Hashim .
Open veterinary journal | 2012
Mahmudul Alam; Mm Rahman
Blood Cells Molecules and Diseases | 2016
Jan Molinsky; Bokang Maswabi; Dana Prukova; Magdalena Klanova; Petra Vockova; Tomas Zikmund; Filipp Savvulidi; Mahmudul Alam; Ludek Sefc; Martin Vokurka; Petra Obrtlikova; Marek Trneny; Pavel Klener
Progressive Agriculture | 2014
A. S. M. Noman; Nasrin Sultana Juyena; Mahmudul Alam; Raihana Nasrin Ferdousy; Sk Paul; Mm Haq
Research in Agriculture, Livestock and Fisheries | 2018
Nazmul Hoda; Zaied Talukder; Pravin Mishra; Mehedi Jaman; Mahmudul Alam
Archive | 2018
Pravin Mishra; Marzia Rahman; Mahmudul Alam